Cargando…

Exploration of the breast ductal carcinoma in situ signature and its prognostic implications

Following the implementation of breast screening programs, the occurrence of ductal carcinoma in situ (DCIS) as an early type of neoplasia has increased. Although the prognosis is promising, 20%–50% of DCIS patients will progress to invasive ductal carcinoma (IDC) if not treated. It is essential to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiao, Lin, Hui, Hou, Lei, Xiao, Hui, Gong, Xilong, Guo, Xuhui, Cao, Xuchen, Liu, Zhenzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939111/
https://www.ncbi.nlm.nih.gov/pubmed/35880695
http://dx.doi.org/10.1002/cam4.5071
_version_ 1784890773616984064
author Zhang, Jiao
Lin, Hui
Hou, Lei
Xiao, Hui
Gong, Xilong
Guo, Xuhui
Cao, Xuchen
Liu, Zhenzhen
author_facet Zhang, Jiao
Lin, Hui
Hou, Lei
Xiao, Hui
Gong, Xilong
Guo, Xuhui
Cao, Xuchen
Liu, Zhenzhen
author_sort Zhang, Jiao
collection PubMed
description Following the implementation of breast screening programs, the occurrence of ductal carcinoma in situ (DCIS) as an early type of neoplasia has increased. Although the prognosis is promising, 20%–50% of DCIS patients will progress to invasive ductal carcinoma (IDC) if not treated. It is essential to look for promising biomarkers for predicting DCIS prognosis. The Gene Expression Omnibus (GEO) database was used to explore the expression of genes that differed between DCIS and normal tissue in this investigation. Enrichment analysis was performed to characterize the biological role and intrinsic process pathway. The Cancer Genome Atlas Breast Cancer Dataset was used to categorize the hub genes, and the results were confirmed using the Cytoscape plugin CytoHubba and MCODE. The prognostic ability of the core gene signature was determined through time‐dependent receiver operating characteristic (ROC), Kaplan–Meier survival curve, Oncomine databases, and UALCAN databases. In addition, the prognostic value of core genes was verified in proliferation assays. We identified 217 common differentially expressed genes (DEGs) in the present study, with 101 upregulated and 138 downregulated genes. The top genes were obtained from the PPI network (protein–protein interaction). A unique six‐gene signature (containing GAPDH, CDH2, BIRC5, NEK2, IDH2, and MELK) was developed for DCIS prognostic prediction. Centered on the Cancer Genome Atlas (TCGA) cohort, the ROC curve showed strong results in prognosis prediction. The six core gene signatures is often overexpressed in DCIS, with a weak prognosis. Furthermore, when breast cancer cells are transfected with small interfering RNAs, downregulation of core gene expression substantially inhibits cell proliferation, revealing a high potential for employing core genes in DCIS prognosis. In conclusion, the current investigation verified the six core genes signatures for prospective DCIS biomarkers, which may aid clinical decision‐making for individual care.
format Online
Article
Text
id pubmed-9939111
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99391112023-02-20 Exploration of the breast ductal carcinoma in situ signature and its prognostic implications Zhang, Jiao Lin, Hui Hou, Lei Xiao, Hui Gong, Xilong Guo, Xuhui Cao, Xuchen Liu, Zhenzhen Cancer Med Research Articles Following the implementation of breast screening programs, the occurrence of ductal carcinoma in situ (DCIS) as an early type of neoplasia has increased. Although the prognosis is promising, 20%–50% of DCIS patients will progress to invasive ductal carcinoma (IDC) if not treated. It is essential to look for promising biomarkers for predicting DCIS prognosis. The Gene Expression Omnibus (GEO) database was used to explore the expression of genes that differed between DCIS and normal tissue in this investigation. Enrichment analysis was performed to characterize the biological role and intrinsic process pathway. The Cancer Genome Atlas Breast Cancer Dataset was used to categorize the hub genes, and the results were confirmed using the Cytoscape plugin CytoHubba and MCODE. The prognostic ability of the core gene signature was determined through time‐dependent receiver operating characteristic (ROC), Kaplan–Meier survival curve, Oncomine databases, and UALCAN databases. In addition, the prognostic value of core genes was verified in proliferation assays. We identified 217 common differentially expressed genes (DEGs) in the present study, with 101 upregulated and 138 downregulated genes. The top genes were obtained from the PPI network (protein–protein interaction). A unique six‐gene signature (containing GAPDH, CDH2, BIRC5, NEK2, IDH2, and MELK) was developed for DCIS prognostic prediction. Centered on the Cancer Genome Atlas (TCGA) cohort, the ROC curve showed strong results in prognosis prediction. The six core gene signatures is often overexpressed in DCIS, with a weak prognosis. Furthermore, when breast cancer cells are transfected with small interfering RNAs, downregulation of core gene expression substantially inhibits cell proliferation, revealing a high potential for employing core genes in DCIS prognosis. In conclusion, the current investigation verified the six core genes signatures for prospective DCIS biomarkers, which may aid clinical decision‐making for individual care. John Wiley and Sons Inc. 2022-07-26 /pmc/articles/PMC9939111/ /pubmed/35880695 http://dx.doi.org/10.1002/cam4.5071 Text en © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Zhang, Jiao
Lin, Hui
Hou, Lei
Xiao, Hui
Gong, Xilong
Guo, Xuhui
Cao, Xuchen
Liu, Zhenzhen
Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title_full Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title_fullStr Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title_full_unstemmed Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title_short Exploration of the breast ductal carcinoma in situ signature and its prognostic implications
title_sort exploration of the breast ductal carcinoma in situ signature and its prognostic implications
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939111/
https://www.ncbi.nlm.nih.gov/pubmed/35880695
http://dx.doi.org/10.1002/cam4.5071
work_keys_str_mv AT zhangjiao explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT linhui explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT houlei explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT xiaohui explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT gongxilong explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT guoxuhui explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT caoxuchen explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications
AT liuzhenzhen explorationofthebreastductalcarcinomainsitusignatureanditsprognosticimplications